Mace

(redirected from Major Adverse Cardiac Events)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.

Mace

A unit of weight in Taiwan approximately equivalent to 3.75 grams. It is used primarily in the sale of bulk foodstuffs.
References in periodicals archive ?
In our study cohort with 1216 T2DM patients, a total of 209 major adverse cardiac events occurred over the initial 3 years following enrollment, and 227 deaths occurred over the ensuing 5 years following enrollment.
Three-year data from the SPIRIT II Trial demonstrated that overall Major Adverse Cardiac Events (MACE), a composite endpoint, favored the PROMUS (XIENCE V) Stent compared to the TAXUS Stent (6.
The Major Adverse Cardiac Events rate for the Sonotherapy arm was 18.
What is an acceptable risk of major adverse cardiac events in chest pain patients soon after discharge from the Emergency Department?
The company said it seeks to utilise its proprietary MicroNet technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
2] at baseline, the primary outcome of three-point major adverse cardiac events occurred in 176 of 1,212 patients in the empagliflozin group (15%), compared with 99 of 607 patients in the placebo group (16%; HR, 0.
The prospective CONFIRM (Coronary CT Evaluation for Clinical Outcomes: An International Multicenter Study) registry of 13,372 patients from 9 countries in Europe, North America and East Asia examined the risk of major adverse cardiac events in 2,853 active smokers, 3,175 past smokers and 7,344 never smokers.
The primary safety end points were infusion-related death due to ventricular tachycardia, ventricular fibrillation, sudden unexpected death, or MI and, at 6-month follow-up, major adverse cardiac events or the formation of cardiac tumors.
Compared to TAXUS, XIENCE V reduced in-stent late loss, or vessel re-narrowing, by 80 percent eight months after the procedure, and reduced major adverse cardiac events by 74 percent at nine months," said Dr.
The trial primary endpoint is Major Adverse Cardiac Events (MACE) at 12 months post-procedure.
The trial's primary efficacy endpoint is a comparison of recurrent non-fatal heart failure-related major adverse cardiac events (HF-MACE) in moderate to advanced CHF patients receiving either MPC-150-IM by catheter injection into the damaged left ventricular heart muscle or sham control.
Full browser ?